Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow A
Agilent Technologies, Inc. (A) EBITDA
Agilent Technologies, Inc.'s EBITDA for fiscal 2025 was $1.8B, unchanged from fiscal 2024. Over the twelve months to 31 July 2026 it was $1.9B. Over the past ten years it has ranged from $775.0M (fiscal 2015) to $1.9B (fiscal 2022); the current reading is higher than 91% of that period. Agilent Technologies, Inc. ranks 6th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.8B | 1.26% |
| FY2024 | $1.7B | 7.65% |
| FY2023 | $1.6B | (16.23%) |
| FY2022 | $1.9B | 16.01% |
| FY2021 | $1.7B | 44.54% |
| FY2020 | $1.2B | (2.12%) |
| FY2019 | $1.2B | 5.83% |
| FY2018 | $1.1B | 9.32% |
| FY2017 | $1.0B | 18.35% |
| FY2016 | $861.0M | 11.10% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jul 2026 | $510.0M | 9.44% |
| Apr 2026 | $466.0M | 10.95% |
| Jan 2026 | $420.0M | (18.29%) |
| Oct 2025 | $514.0M | 18.98% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| A Agilent Technologies, Inc. | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on A
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement